GRACE :: Global Resource for Advancing Cancer Education
Share
  • Recent GRACE News & Posts

    • How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow? [GRACE :: Lung Cancer]
      Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes how he helps his EGFR lung cancer patients make decisions about next steps in treatment when their cancers grow. [powerpress]
    • FGFR and Its Role in Treating Squamous Cell Lung Cancer [GRACE :: Lung Cancer]
      Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area. [powerpress]
    • What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer? [GRACE :: Lung Cancer]
      "HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014. [powerpress]
    • The Promise of Immunotherapy in Lung Cancer [GRACE :: Lung Cancer]
      Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014. [powerpress]
    • Immunotherapy Treatments for Kidney Cancer [GRACE :: Kidney Cancer]
      Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting. [powerpress]
    • DDR2 Mutations in Squamous Cell Lung Cancer [GRACE :: Lung Cancer]
      A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients. [powerpress]
    • University of Colorado’s Online Screening for Rare Lung Cancer Subtypes Opens Door to New Kind of Clinical Trial [GRACE :: Lung Cancer]
      The following piece is from the University of Colorado, where Dr. Camidge and some others there are leading a very novel trial for a small molecularly defined subgroup with specific biomarkers related to fibroblast growth factor receptor-1 (FGFR1) are potential candidates for a trial just launching now with the agent ponatinib, a tyrosine kinase inhibitor (TKI) that hits many t
    • Evaluating Biomarkers in Kidney Cancer [GRACE :: Kidney Cancer]
      Biomarkers can give clues to many predictive and prognostic issues, like how a patient may respond to a drug or if a patient's cancer is likely to recur. Dr. Daniel Heng discusses what researchers are learning. [powerpress]
    • Will Combining Immunotherapies Better Fight Kidney Cancer? [GRACE :: Kidney Cancer]
      Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients. [powerpress]
    • Cabozantinib for Late Stage Kidney Cancer [GRACE :: Kidney Cancer]
      Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer. [powerpress]
    • Immunotherapy: What Has a Year’s Experience Taught Us Since ASCO 2013? [GRACE :: Lung Cancer]
      Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013. [powerpress]
    • How much evidence is needed to change practice in cancer care? 8 key factors help set the bar. [GRACE :: Cancer Basics]
      The concept of statistical significance, a line drawn at the level of less than 5% probability that the effects of a new approach could be due to chance alone and not the intervention itself, implies that there's a point of demarcation where we considera result positive. In truth, however, science and medicine are far messier than that, and we see adoption of new tests and new